Chest
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The most common autoimmune inflammatory demyelinating disease of the central nervous system is multiple sclerosis. It has a unique clinical feature of unpredictable exacerbations and remissions. Systemic infectious process is one of the important precipitating factors for multiple sclerosis exacerbation1. ⋯ Our case report reflects the association of a multiple sclerosis exacerbation with an underlying infectious process. The patient's neurological findings significantly improved following treatment of the empyema. Early detection and adequate treatment of systemic infection is a cornerstone of multiple sclerosis exacerbation management.Reference #1: Buljevac D, Flach HZ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain. 2002;125(Pt 5):952-960Reference #2: Correale J, Fiol M, et al. The risk of relapses in multiple sclerosis during systemic infections. Neurology. 2006;67(4):652-659DISCLOSURE: The following authors have nothing to disclose: Debjit Saha, Jillian Cepeda, Daisha Hayden, Ari CimentNo Product/Research Disclosure Information.
-
COPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Osteoporosis has a higher prevalence in COPD patients and its etiology is very complex, it has been linked with reduced physical activity, low body mass index (BMD), a worse degree of airflow limitation and glucocorticosteroids treatment. The main objective was to describe the biochemical markers of bone turnover and a Lateral Dual energy X-ray absorptiometry (DXA) scan in COPD patients, and related them. ⋯ The following authors have nothing to disclose: Emma Vazquez, Rosa Mar Gomez Punter, Rosa Girón Moreno, Silvia Sanchez, Cristina Lopez Riolobos, Julio Ancochea BermúdezNo Product/Research Disclosure Information.
-
Rare Disease Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Amyloid Cardiomyopathy is characterized by bi-ventricular thickening due to amyloid deposition leading to diastolic dysfunction. ⋯ Cardiac amyloidosis should be considered in any adult with unexplained heart failure and an echocardiogram showing increased wall thickness with a nondilated left ventricular cavity, particularly when associated with low voltage on electrocardiogram.Reference #1: N/ADISCLOSURE: The following authors have nothing to disclose: Sameer Chadha, On Chen, Sunday Olatunde, Adnan Sadiq, Gerald Hollander, Jacob ShaniNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe-to-very severe COPD require intensified therapy to reduce risk of exacerbations. Such patients may benefit from additional bronchodilation. Once-daily QVA149 is a dual bronchodilator consisting of a fixed-dose combination of two long-acting bronchodilators, indacaterol and glycopyrronium. ⋯ Jadwiga Wedzicha: Consultant fee, speaker bureau, advisory committee, etc.: JW has received speaking fee and/or for advisory boards from GlaxoSmithKline, AstraZeneca, Novartis, Bayer, Boehringer Ingelheim, Nycomed. Chiesi and Respifor as well as travel reimbursements from Boehringer Ingelheim. JW has received research grants from GlaxoSmithKline, AstraZeneca, Chiesi and Novartis. Joachim Ficker: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Ficker has received speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Nycomed, Almirall, Berlin-C hemie, Takeda and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Angel FowlerTaylor: Employee: The author is an employee of Novartis Pharmaceuticals Corporation Donald Banerji: Employee: The author is an employee of Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Dennis Niewohner, Thomas SandströmClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Cancer Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Primary paraganglioma of the lung is a rare tumor of which few cases are reported in literature. ⋯ The following authors have nothing to disclose: Giuseppe Fiorentino, Anna Annunziata, Rosa Cauteruccio, Raffaele Cobuccio, Mario CaputiNo Product/Research Disclosure Information.